Documentation Centre

May 15, 2019
Targeting PCSK9 to reduce residual risk in ACS. Nat Rev Cardiol. 2019;16:2
Fernández-Ruiz I

Description of this Publication

Consult publication on external website

By clicking on this link, you will leave the INTERNATIONAL CHAIR ON CARDIOMETABOLIC RISK website

Key Words
Cardiovascular Disease, Clinical Cardiology, Lipids/Lipoproteins